MarketBeat estimates results for Trevena stock

Published on 10/14/2026 at 02:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MarketBeat estimated a November 5, 2026 report date for Trevena stock. The last quote was USD 0.07 after USD 0.01.

Trevena earnings date and estimates

MarketBeat estimated a November 5, 2026 earnings report for Trevena.
Consensus estimates call for negative USD 50.00 per share and USD 0.78 million in revenue.
Trevena stock was last quoted at USD 0.07 at OTC Markets on October 12, 2026 at 2:57 p.m. ET after USD 0.01.

TRVN, US89532E3071, Illustration mit AI erstellt.

MarketBeat estimated on October 13, 2026 that Trevena will report earnings on November 5, 2026. The date gives Trevena stock a defined reporting marker while the company continues to center its pipeline on central nervous system medicines.

November 5 report date

The date is an estimate based on past reporting schedules, according to MarketBeat, rather than a confirmed company announcement. Its earnings page lists consensus expectations of negative USD 50.00 per share and USD 0.78 million in revenue for the upcoming report.

Those estimates carry substantial uncertainty because the same page identifies the last reported period as the third quarter of 2024. Trevena reported historical revenue of USD 0.28 million and a historical loss of USD 5.79 per share for that quarter, giving investors two concrete benchmarks for the November update.

What does the pipeline include?

Trevena's investor-relations page describes OLINVYK as an FDA-approved treatment for acute pain and lists three investigational programs: TRV250 for migraine, TRV734 for opioid use disorder and TRV045 for chronic pain-related conditions. The company also presents four novel drug development programs in its corporate overview, according to Trevena.

For investors, the central question is whether the next report supplies operating evidence behind that pipeline. The consensus revenue figure of USD 0.78 million is higher than the historical third-quarter revenue of USD 0.28 million, while the consensus loss estimate of negative USD 50.00 per share is materially below the historical loss of USD 5.79 per share.

Last quoted price and dates

Trevena stock was last quoted at USD 0.07 on OTC Markets on October 12, 2026 at 2:57 p.m. ET, after USD 0.01. MarketBeat lists November 5, 2026 as the estimated earnings date, while Trevena's investor-relations page identifies the third quarter of 2024 as the latest reported period.

Market report S&P 500.